Skip to main navigation Skip to search Skip to main content

Evaluation of a 13-hexyl-berberine hydrochloride topical gel formulation

  • Hui Lin Wei
  • , Shuqi Wang
  • , Feng Xu
  • , Lan Fang Xu
  • , Jia Run Zheng
  • , Yun Chen
  • Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
  • Brunswick Labs
  • Brigham and Women’s Hospital

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

13-hexyl-berberine hydrochloride (HB-13) is a derivative from berberine which finds widespread applications in the treatment of infectious pathogens including fungi, bacteria, parasites and viruses. As our continuing efforts for treatment of herpes simplex virus (HSV), we studied the topical delivery and safety of HB-13 in a gel formulation (0.5%) in a pig model. Our studies demonstrated the maximal HB-13 concentration was 2.51 g/mL, which was more than the half maximal inhibitory concentration (IC50) as we previously reported. In addition, there was no sign of irritation or histological aberrance for stripped skin continuously applied with 0.5% HB-13 gel for 21 days. In conclusion, 0.5% HB-13 gel can achieve effective anti-HSV concentration in the dermis and it is safe to use.

Original languageEnglish
Pages (from-to)534-539
Number of pages6
JournalDrug Development and Industrial Pharmacy
Volume39
Issue number4
DOIs
StatePublished - Apr 2013

Keywords

  • 13-hexyl-berberine hydrochloride (HB-13)
  • Gel
  • Microdialysis
  • Pig
  • Safety

Fingerprint

Dive into the research topics of 'Evaluation of a 13-hexyl-berberine hydrochloride topical gel formulation'. Together they form a unique fingerprint.

Cite this